Add this topic to your myFT Digest for news straight to your inbox
When costs gobble up all the alpha
The axe is hanging over high-growth companies with stretched valuations
The iShares ETF will quit the Dow Jones benchmark and move to a cap-weighted S&P rival
No shortage of theories why investors think big tech is still a good bet
Raytheon and Pfizer also on the way out in reshuffle prompted by Apple stock split
International Edition